Skip to main content
Top
Published in: Child's Nervous System 7/2017

01-07-2017 | Case Report

Finding of IDH1 R132H mutation in histologically non-neoplastic glial tissue changes surgical strategies, a case report

Authors: Christian Baastrup Søndergaard, David Scheie, Astrid Marie Sehested, Jane Skjøth-Rasmussen

Published in: Child's Nervous System | Issue 7/2017

Login to get access

Abstract

Introduction

In 2016, the WHO classification of diffuse astrocytoma began to include isocitrate dehydrogenase (IDH) mutation in addition to histology.

Results

We here demonstrate a case where a 14-year-old boy presented with a parietal tumor with no histological evidence of neoplasia but with an IDH1 mutation. Due to the IDH1 R132H mutation, the patient was diagnosed with diffuse astrocytoma WHO grade II and underwent successful gross total resection of this near-eloquently located tumor.

Conclusion

This case exemplifies how inclusion of immunohistochemistry in tumor classification alters surgical strategy and might improve accuracy and time to diagnosis.
Literature
1.
go back to reference Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820CrossRefPubMed Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820CrossRefPubMed
2.
go back to reference Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109CrossRefPubMedPubMedCentral Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109CrossRefPubMedPubMedCentral
3.
go back to reference Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118(4):469–474CrossRefPubMed Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118(4):469–474CrossRefPubMed
4.
go back to reference Juratli TA, Cahill DP, McCutcheon IE (2015) Determining optimal treatment strategy for diffuse glioma: the emerging role of IDH mutations. Expert Rev Anticancer Ther 15(6):603–606CrossRefPubMedPubMedCentral Juratli TA, Cahill DP, McCutcheon IE (2015) Determining optimal treatment strategy for diffuse glioma: the emerging role of IDH mutations. Expert Rev Anticancer Ther 15(6):603–606CrossRefPubMedPubMedCentral
6.
go back to reference Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118(5):599–601CrossRefPubMed Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118(5):599–601CrossRefPubMed
7.
go back to reference Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Louis DN, Nutt CL (2010) Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathol 119(4):509–511CrossRefPubMedPubMedCentral Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Louis DN, Nutt CL (2010) Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathol 119(4):509–511CrossRefPubMedPubMedCentral
8.
go back to reference Jakola AS, Unsgard G, Myrmel KS, Kloster R, Torp SH, Losvik OK et al (2013) Surgical strategy in grade II astrocytoma: a population-based analysis of survival and morbidity with a strategy of early resection as compared to watchful waiting. Acta Neurochir 155(12):2227–2235CrossRefPubMed Jakola AS, Unsgard G, Myrmel KS, Kloster R, Torp SH, Losvik OK et al (2013) Surgical strategy in grade II astrocytoma: a population-based analysis of survival and morbidity with a strategy of early resection as compared to watchful waiting. Acta Neurochir 155(12):2227–2235CrossRefPubMed
9.
go back to reference Aghi MK, Nahed BV, Sloan AE, Ryken TC, Kalkanis SN, Olson JJ (2015) The role of surgery in the management of patients with diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol 125(3):503–530CrossRef Aghi MK, Nahed BV, Sloan AE, Ryken TC, Kalkanis SN, Olson JJ (2015) The role of surgery in the management of patients with diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol 125(3):503–530CrossRef
10.
go back to reference Duffau H (2016) Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up. Acta Neurochir 158(1):51–58CrossRefPubMed Duffau H (2016) Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up. Acta Neurochir 158(1):51–58CrossRefPubMed
Metadata
Title
Finding of IDH1 R132H mutation in histologically non-neoplastic glial tissue changes surgical strategies, a case report
Authors
Christian Baastrup Søndergaard
David Scheie
Astrid Marie Sehested
Jane Skjøth-Rasmussen
Publication date
01-07-2017
Publisher
Springer Berlin Heidelberg
Published in
Child's Nervous System / Issue 7/2017
Print ISSN: 0256-7040
Electronic ISSN: 1433-0350
DOI
https://doi.org/10.1007/s00381-017-3348-7

Other articles of this Issue 7/2017

Child's Nervous System 7/2017 Go to the issue